8.80
Sage Therapeutics Inc stock is traded at $8.80, with a volume of 2.93M.
It is up +0.46% in the last 24 hours and down -4.86% over the past month.
Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; also targeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. Its products ZURZUVAE is a medicine for the treatment of postpartum depression, or PPD, in adults, and ZULRESSO is a CIV injection for the treatment of postpartum depression in individuals 15 years old and older. It also has other drugs in its pipeline such as SAGE-324, Dalzanemdor (SAGE-718) among others.
See More
Previous Close:
$8.76
Open:
$8.79
24h Volume:
2.93M
Relative Volume:
1.59
Market Cap:
$551.06M
Revenue:
$91.06M
Net Income/Loss:
$-503.14M
P/E Ratio:
-1.0489
EPS:
-8.39
Net Cash Flow:
$-424.74M
1W Performance:
-3.40%
1M Performance:
-4.86%
6M Performance:
+23.94%
1Y Performance:
-15.95%
Sage Therapeutics Inc Stock (SAGE) Company Profile
Name
Sage Therapeutics Inc
Sector
Industry
Phone
617-299-8380
Address
55 CAMBRIDGE PARKWAY, CAMBRIDGE, MA
Compare SAGE with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
SAGE
Sage Therapeutics Inc
|
8.80 | 548.57M | 91.06M | -503.14M | -424.74M | -8.39 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 121.28B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
291.47 | 32.08B | 3.81B | -644.79M | -669.77M | -6.24 |
Sage Therapeutics Inc Stock (SAGE) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Mar-11-25 | Resumed | BofA Securities | Underperform |
Nov-21-24 | Upgrade | RBC Capital Mkts | Underperform → Sector Perform |
Oct-10-24 | Resumed | Raymond James | Mkt Perform |
Oct-04-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
Jul-30-24 | Downgrade | TD Cowen | Buy → Hold |
Jul-25-24 | Downgrade | JP Morgan | Overweight → Neutral |
May-29-24 | Initiated | Citigroup | Sell |
May-29-24 | Initiated | Robert W. Baird | Neutral |
Apr-17-24 | Downgrade | BofA Securities | Neutral → Underperform |
Dec-12-23 | Initiated | Deutsche Bank | Hold |
Aug-08-23 | Downgrade | Canaccord Genuity | Buy → Hold |
Aug-08-23 | Downgrade | Goldman | Buy → Neutral |
Aug-08-23 | Downgrade | Needham | Buy → Hold |
Aug-07-23 | Downgrade | BofA Securities | Buy → Neutral |
Aug-07-23 | Downgrade | Oppenheimer | Outperform → Perform |
Aug-07-23 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
Aug-07-23 | Downgrade | Stifel | Buy → Hold |
Aug-07-23 | Downgrade | Wedbush | Outperform → Neutral |
Jul-27-23 | Initiated | Scotiabank | Sector Outperform |
Mar-13-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
Jan-03-23 | Downgrade | Guggenheim | Buy → Neutral |
Nov-01-22 | Initiated | Loop Capital | Hold |
Mar-31-22 | Initiated | Berenberg | Hold |
Nov-02-21 | Upgrade | Guggenheim | Neutral → Buy |
Oct-19-21 | Resumed | Morgan Stanley | Equal-Weight |
Oct-07-21 | Downgrade | Jefferies | Buy → Hold |
Sep-23-21 | Initiated | Needham | Buy |
Jun-16-21 | Downgrade | Citigroup | Buy → Neutral |
Apr-07-21 | Initiated | Piper Sandler | Overweight |
Feb-26-21 | Downgrade | Mizuho | Buy → Neutral |
Feb-25-21 | Reiterated | H.C. Wainwright | Neutral |
Feb-02-21 | Resumed | Raymond James | Mkt Perform |
Jan-22-21 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
Jan-04-21 | Upgrade | Guggenheim | Neutral → Buy |
Jan-04-21 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
Dec-04-20 | Upgrade | Mizuho | Neutral → Buy |
Dec-01-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
Nov-16-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
Nov-06-20 | Reiterated | H.C. Wainwright | Neutral |
Sep-11-20 | Upgrade | Wedbush | Neutral → Outperform |
Aug-10-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
May-08-20 | Downgrade | Wedbush | Outperform → Neutral |
Apr-08-20 | Downgrade | Guggenheim | Buy → Neutral |
Mar-18-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
Mar-06-20 | Initiated | Citigroup | Buy |
Feb-28-20 | Reiterated | H.C. Wainwright | Neutral |
Feb-06-20 | Initiated | Mizuho | Neutral |
Dec-06-19 | Reiterated | RBC Capital Mkts | Outperform |
Dec-05-19 | Reiterated | Guggenheim | Buy |
Dec-05-19 | Downgrade | SunTrust | Buy → Hold |
Oct-30-19 | Initiated | H.C. Wainwright | Neutral |
May-23-19 | Initiated | Wedbush | Outperform |
Apr-25-19 | Initiated | Jefferies | Buy |
Dec-14-18 | Initiated | Wolfe Research | Outperform |
Oct-11-18 | Initiated | Oppenheimer | Outperform |
View All
Sage Therapeutics Inc Stock (SAGE) Latest News
BML Capital Management LLC Buys New Shares in Sage Therapeutics, Inc. (NASDAQ:SAGE) - MarketBeat
Sage Therapeutics (NASDAQ:SAGE) Sees Unusually-High Trading VolumeShould You Buy? - MarketBeat
Sage Therapeutics (SAGE) Expected to Announce Earnings on Wednesday - MarketBeat
Cwm LLC Acquires 58,410 Shares of Sage Therapeutics, Inc. (NASDAQ:SAGE) - MarketBeat
What drives Sage Therapeutics Inc. stock priceUnbelievable profit margins - Autocar Professional
What analysts say about Sage Therapeutics Inc. stockFree Investment Community - Autocar Professional
Sage Therapeutics Inc. Stock Analysis and ForecastMarket-beating returns - jammulinksnews.com
Is Sage Therapeutics Inc. a good long term investmentFree Daily Trading Room Entry - jammulinksnews.com
Layoff Tracker: GSK, Sail, BioNTech Cut Staff for Second Time This Year - BioSpace
Sage Therapeutics (NASDAQ:SAGE) Stock Price Crosses Above 50 Day Moving AverageHere's Why - MarketBeat
ALERT: Rowley Law PLLC Is Investigating Proposed Acquisition of Sage Therapeutics, Inc. - 富途牛牛
Status Epilepticus Pipeline 2025: Key Companies, MOA, ROA, - openPR.com
Status Epilepticus Pipeline 2025: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | Marinus Pharmac, Pfizer, UCB Biopharma, Rafa Laboratories, Sage Therapeutics - The Globe and Mail
SAGE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sage Therapeutics, Inc.SAGE - Business Wire
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Sage Therapeutics, Inc. (SAGE) And Encourages Stockholders to Reach Out - ACCESS Newswire
Sage Therapeutics (NASDAQ:SAGE) Downgraded to Hold Rating by Scotiabank - MarketBeat
SAGE Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Sage Therapeutics, Inc. is Fair to Shareholders - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating Sage Therapeutics, Inc. (SAGE) And Encourages Shareholders to Connect - ACCESS Newswire
Sage Therapeutics, Inc. (NASDAQ:SAGE) Receives Average Rating of "Reduce" from Analysts - MarketBeat
Sage Therapeutics (NASDAQ:SAGE) Rating Lowered to “Hold” at Scotiabank - Defense World
Sage Therapeutics Announces Workforce Reductions Following Recent Acquisition Plans - geneonline.com
Postpartum Depression Pipeline 2025: Detailed Clinical Trials and FDA-Approved Therapies Review by DelveInsight | SAGE Therapeutics, Brii Biosciences Limited, Reunion Neuroscience, GH Research - Barchart.com
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Sage Therapeutics, Inc. (SAGE) And Encourages Shareholders to Reach Out - ACCESS Newswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates NVEE, SAGE, OLO on Behalf of Shareholders - Morningstar
Beyond The Numbers: 6 Analysts Discuss Sage Therapeutics Stock - Nasdaq
SAGE: Scotiabank Downgrades Sage Therapeutics with Price Target Adjustment | SAGE Stock News - GuruFocus
Scotiabank Downgrades SAGE Therapeutics to Sector Perform From Sector Outperform, Adjusts Price Target to $9.20 From $12 - MarketScreener
Wealth Enhancement Advisory Services LLC Takes $347,000 Position in Sage Therapeutics, Inc. (NASDAQ:SAGE) - Defense World
Scotiabank Downgrades Sage Therapeutics (SAGE) - MSN
Sage Therapeutics (NASDAQ:SAGE) Share Price Passes Above Two Hundred Day Moving AverageShould You Sell? - MarketBeat
Sage Therapeutics' Q1 Earnings Miss Mark, Revenue Rise Y/Y - MSN
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sage Therapeutics, Inc. (SAGE) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Sage Therapeutics, Inc. (NASDAQ:SAGE) Receives Consensus Rating of “Hold” from Analysts - Defense World
Sage Therapeutics, Inc. (SAGE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger: CARM, GNTY, TSBX, and SAGE - Eastern Progress
Sage Therapeutics, Inc. (SAGE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
What Makes Sage Therapeutics (SAGE) a New Buy Stock - Yahoo Finance
Sage to lay off most staff amid Supernus buyout - BioPharma Dive
Levi & Korsinsky Reminds Sage Therapeutics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 28, 2024 – SAGE - ACCESS Newswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
Sage Therapeutics Inc Stock (SAGE) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):